Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Parenthetical)

v3.7.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Advances on research and development contract services, from Theradex   $ 181,510
Research and development contract liabilities, Theradex   $ 33,216
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 57,875,814 47,875,814
Common stock, shares outstanding 57,875,814 47,875,814
Series A Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, stated value 10.00 10.00
Preferred stock, per share redemption price $ 50.00 $ 50.00
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 350,000 350,000
Preferred stock, shares outstanding 350,000 350,000
Preferred stock, aggregate redemption value $ 17,500,000 $ 17,500,000
Preferred stock, issuable upon conversion 4,375,000 4,375,000